Home › Biology

📖 3 min read

NAFLD: enzyme NNMT linked to fat buildup via NAD+ depletion

The key finding

Researchers have identified nicotinamide N-methyltransferase (NNMT) as a central driver in non-alcoholic fatty liver disease (NAFLD), the most common liver disorder worldwide. This enzyme disrupts metabolism by depleting NAD+—a molecule cells need for energy production—while simultaneously interfering with methylation processes that regulate gene expression. In animal studies, knocking out NNMT reduced hepatic fat accumulation, inflammation, and fibrosis, whereas overexpressing the enzyme worsened metabolic dysfunction. The finding suggests NNMT operates through at least four interconnected pathways: NAD+ metabolism, methionine cycling, epigenetic modifications, and gut microbiota interactions.

What the study looked like

This 2025 review synthesizes evidence from preclinical studies, primarily rodent models, examining NNMT’s role in NAFLD pathogenesis. Researchers analyzed experiments where NNMT was genetically knocked out or overexpressed in mice with diet-induced fatty liver disease. The studies measured hepatic lipid content, inflammation markers, fibrosis progression, NAD+ levels, and metabolites like S-adenosylmethionine (SAM) and homocysteine. Additional experiments tracked how NNMT activity altered gut microbiota composition, bile acid metabolism, and intestinal barrier function. The review also evaluated early-stage therapeutic candidates including antisense oligonucleotides and small-molecule NNMT inhibitors tested in animal models for anti-steatotic and anti-fibrotic effects.

Why researchers think this happened

NNMT catalyzes a reaction that converts nicotinamide (a form of vitamin B3) into methylnicotinamide, consuming SAM in the process. This depletes the cellular pool of SAM—the universal methyl donor for DNA and histone modifications—while raising homocysteine levels and oxidative stress. Simultaneously, the conversion reduces NAD+ availability, impairing enzymes like SIRT1 and PARPs that regulate mitochondrial function, insulin signaling, and cellular repair. The researchers propose that this dual disruption creates a metabolic cascade: reduced NAD+ hampers energy metabolism, while SAM depletion alters epigenetic programming in ways that favor fat storage. NNMT also appears to influence gut bacteria in ways that disturb bile acid processing and intestinal permeability, allowing inflammatory signals to reach the liver via the gut-liver axis—a feedback loop that amplifies hepatic lipid accumulation.

How to read this carefully

The evidence comes almost entirely from animal models, so direct applicability to human NAFLD remains uncertain. Genetic knockout studies show what happens when NNMT is completely absent, but therapeutic interventions would likely reduce rather than eliminate enzyme activity—effects that may differ substantially. The review notes that NNMT inhibitors tested so far suffer from limited selectivity and poor stability in living organisms, meaning they haven’t successfully transitioned to human trials. Additionally, NAFLD is a heterogeneous condition influenced by diet, genetics, obesity, and insulin resistance; NNMT may play varying roles across patient subgroups. Correlation between NNMT levels and disease severity doesn’t prove the enzyme causes progression, and the gut microbiota findings require replication in human cohorts with diverse dietary patterns.

What this means for everyday life

While no NNMT-targeted therapies are available clinically, this research underscores how tightly cellular energy metabolism, methylation chemistry, and liver health are linked. The connection to NAD+ is particularly intriguing given ongoing interest in NAD+ precursors like nicotinamide riboside for metabolic health—though this paper suggests NNMT activity might counteract such supplements by converting nicotinamide into an inactive form. For those managing or at risk for fatty liver disease, the findings reinforce that liver fat accumulation isn’t simply about calories in versus out; it involves complex enzyme networks, gut health, and epigenetic regulation. Given these mechanisms, it might be worth considering lifestyle factors known to support NAD+ levels and methylation—adequate B-vitamin intake, gut microbiome diversity through fiber, and metabolic health markers like insulin sensitivity—while awaiting targeted therapies that could one day modulate NNMT safely in humans.


Source

  • PMID: 40706948 (read full paper on PubMed)
  • Journal: Archives of biochemistry and biophysics (2025)

Articles on this site are adapted from PubMed abstracts as general-interest explainers. They are not intended as medical advice.

📝 This article was adapted by the PubMed Trivia editorial team using Claude (Anthropic) as an adaptation assistant, based on the PubMed abstract cited above. Our editorial workflow includes automated NG-term checks (medical-claims law), careful "correlation vs causation" distinction, and mandatory PMID + source URL disclosure. See the full pipeline on our editorial policy and editor pages. Please report errors to sciencepubmedjp@gmail.com (we respond within 48 hours).